FDA To Review Gilead’s Ambrisentan And Encysive’s Thelin Back-To-Back

The agency granted Gilead’s pulmonary hypertension candidate a priority review, setting a June 18 user fee date that falls days after the review timeline for Thelin.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet